Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging

Thomas D Harris1, Edward Cheesman, Anthony R Harris

  • 1Discovery Research, Bristol-Myers Squibb Medical Imaging, North, Billerica, Massachusetts 01862, USA. tdharris911@comcast.net

Insights

New divalent integrin alphavbeta3 antagonists show enhanced tumor uptake and retention compared to the original TA138. These radiolabeled agents offer improved tumor targeting and therapeutic potential for cancer treatment.

Area of Science:

  • Biomedical Imaging
  • Radiopharmaceutical Chemistry
  • Oncology

Background:

  • Integrin alphavbeta3 is a key target in cancer, overexpressed on tumor vasculature and cells.
  • TA138, a radiolabeled alphavbeta3 antagonist, shows high affinity and selectivity, with good tumor uptake in preclinical models.

Purpose of the Study:

  • To synthesize and evaluate novel divalent versions of TA138 as potential tumor radiotherapeutic agents.
  • To investigate the impact of spacer length and molecular charge on the efficacy of these new agents.

Main Methods:

  • Synthesis of eight divalent TA138 analogs with varying spacer lengths and charges.
  • Evaluation of receptor affinity using integrin receptor binding assays.
  • Biodistribution studies of 111In-labeled derivatives in the c-neu Oncomouse model.

Main Results:

  • All divalent agents retained high affinity and selectivity for integrin alphavbeta3.
  • Six of eight agents showed faster blood clearance than 111In-TA138 at 24 hours postinjection.
  • Divalent agents exhibited higher tumor uptake and retention, with improved tumor-to-organ ratios, especially those with intermediate spacers.

Conclusions:

  • Divalent TA138 analogs demonstrate enhanced tumor targeting and retention compared to the parent compound.
  • These agents hold promise for improved radiotherapeutic applications in cancer treatment.
  • The multivalent effect contributes to improved therapeutic indices, suggesting potential for enhanced efficacy.